Literature DB >> 17332702

[Abnormalities in lymphocyte telomerase activity and telomere length in systemic lupus erythematosus].

Daitaro Kurosaka1.   

Abstract

T-cell telomerase activity was high in the active and inactive stages of systemic lupus erythematosus (SLE). In contrast, B-cell telomerase activity was very high only in the active stage. Compared with normal subjects, SLE patients had a shorter T-cell telomere, but their B-cell telomere length did not differ from that of normal subjects. These findings suggest that T cells are always activated, and that the manifestation of the disease requires the activation of not only T but also B cells. B-cell inhibition alone may be sufficient to suppress the clinical symptoms of SLE, but we consider that the essential treatment of SLE should target T cells as well. In recent years, various biologicals have begun to be used for the treatment of SLE. It is interesting how the use of such biologicals in the future will change T- and B-cell telomerase activity. In formulating a therapeutic strategy using biologicals for SLE, the measurement of telomerase activity in T and B cells seems useful for the preparation of target cells, selection of therapeutic drugs, and evaluation of therapeutic responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332702     DOI: 10.2177/jsci.30.29

Source DB:  PubMed          Journal:  Nihon Rinsho Meneki Gakkai Kaishi        ISSN: 0911-4300


  2 in total

1.  Expression Pattern of Telomerase Reverse Transcriptase (hTERT) Variants and Bcl-2 in Peripheral Lymphocytes of Systemic Lupus Erythematosus Patients.

Authors:  Armin Attar; Mohsen Khosravi Maharlooei; Mohammad Ali Nazarinia; Ahmad Hosseini; Zohre Bajalli; Yalda Sadat Moeini; Ahmad Monabati; Fatemeh Amirmoezi; Mansooreh Jaberipour; Mojtaba Habibagahi
Journal:  Iran J Pathol       Date:  2020-04-21

Review 2.  Molecular and Cellular Bases of Immunosenescence, Inflammation, and Cardiovascular Complications Mimicking "Inflammaging" in Patients with Systemic Lupus Erythematosus.

Authors:  Chang-Youh Tsai; Chieh-Yu Shen; Hsien-Tzung Liao; Ko-Jen Li; Hui-Ting Lee; Cheng-Shiun Lu; Cheng-Han Wu; Yu-Min Kuo; Song-Chou Hsieh; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.